Rafael Holdings Inc (RFL) Stock Price, Quote & News

Company Profile

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is Trappsol Cyclo, which is in phase 3 clinical trial being evaluated for t...

Industry: Real Estate Services

Sector: Real Estate

Phone: 212 658 1450

Website: www.rafaelholdings.com

Address:

520 Broad Street, Newark, United States

AnthonyRogers215 Feb. 21 at 8:55 AM

$RFL Rafael Holdings invests in healthcare assets. Valuation depends on subsidiary performance. Complexity adds risk.

0 · Reply

sg44 Feb. 20 at 2:54 PM

$RFL

0 · Reply

Logan_Rippenkroger Feb. 20 at 7:33 AM

$RFL https://www.linkedin.com/feed/update/ugcPost:7429547722858471426?trk=feed_main-feed-card_social-actions-comments Surprised I haven’t see this posted. Scroll through the comments….

1 · Reply

northmark1 Feb. 19 at 6:56 PM

$RFL How Many Ways Can You Spell Failure RFL!

0 · Reply

CaseOfTheYips1 Feb. 19 at 5:25 PM

$RFL 10K shares on a coma pulse…

0 · Reply

GDS_investing Feb. 19 at 3:30 PM

$RFL looking good reversal mode need more volume need to cross 1.32 for fast runup LONG

0 · Reply

sg44 Feb. 18 at 12:56 PM

$RFL institutions were net sellers in Q4. Vanguard, Geode had decent increases. Tutes own about 4M, Insiders 30M or 35M and retail 15M or 10M shares. A very different mix of owners compared to most other stocks.Good luck longs.

0 · Reply

equtz Feb. 18 at 1:12 AM

$RFL this is probably junk but if nothing happens soon the bottom will fall out. buying with stops in place, but 50 cent downside with 3 point upside is a good spec, imo

0 · Reply

sg44 Feb. 17 at 10:56 PM

$RFL

0 · Reply

CaseOfTheYips1 Feb. 17 at 10:02 PM

$RFL presentation was a whopper… 👎🏽 Next milestone is the quarterly this week or next… not expecting much there… then Apr-Jun should have readout and our fates sealed…

0 · Reply

Rafael Holdings Reports First Quarter Fiscal 2026 Financial Results

Oct 29, 2025, 4:24 PM EDT - 4 months ago

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results

Oct 28, 2025, 4:01 PM EDT - 4 months ago

Rafael Holdings Mourns the Passing of Lead Independent Director, Stephen Greenberg, and Announces the Appointment of Alan Grayson to its Board of Directors

Sep 16, 2025, 8:00 AM EDT - 5 months ago

Rafael Holdings Announces Presentation of Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label, Single-Arm Sub-Study in Patients Less Than 3 Years Old

Aug 27, 2025, 8:00 AM EDT - 6 months ago

Rafael Holdings Announces Abstracts Accepted for Oral and Poster Presentations at the 15th International Congress of Inborn Errors of Metabolism (ICIEM)

Jun 11, 2025, 7:00 AM EDT - 9 months ago

Rafael Holdings Reports Third Quarter Fiscal 2025 Financial Results

Jun 4, 2025, 4:01 PM EDT - 9 months ago

Rafael Holdings, Inc. Announces Final Results and Closing of Rights Offering

May 20, 2025, 4:01 PM EDT - 9 months ago

Rafael Holdings, Inc. Provides Update to the Description of Subscription Rights Related to its Public Warrants in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

May 5, 2025, 7:00 AM EDT - 10 months ago

Rafael Holdings, Inc. Announces Revised Subscription Rights in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

Apr 29, 2025, 4:30 PM EDT - 10 months ago

Rafael Holdings, Inc. Announces Proposed Terms of a $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

Apr 24, 2025, 4:15 PM EDT - 10 months ago

Rafael Holdings Strengthens its Focus on the Development of Trappsol® Cyclo™ and Announces Chief Executive Officer Bill Conkling Will Be Stepping Down from His Role

Mar 26, 2025, 6:50 AM EDT - 11 months ago

Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals

Mar 13, 2025, 5:50 PM EDT - 1 year ago

Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results

Feb 20, 2025, 4:35 PM EST - 1 year ago

CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH

CYTH

Dec 11, 2024, 7:00 AM EST - 1 year ago

Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results

Nov 6, 2024, 7:14 PM EST - 1 year ago

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results

Oct 2, 2024, 12:00 PM EDT - 1 year ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MNTX and RFL on Behalf of Shareholders

MNTX

Aug 22, 2024, 10:19 AM EDT - 1 year ago

Accession Risk Management Group Closes $1 Billion Financing to Further Accelerate Growth of Risk Strategies and One80 Intermediaries

CYTH

Aug 22, 2024, 6:50 AM EDT - 1 year ago

Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement

CYTH

Aug 22, 2024, 6:50 AM EDT - 1 year ago

Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement

Jun 14, 2024, 4:01 PM EDT - 1 year ago

Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results

Mar 13, 2024, 5:04 PM EDT - 2 years ago

Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results

Dec 14, 2023, 4:01 PM EST - 2 years ago

Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results

Oct 30, 2023, 4:01 PM EDT - 2 years ago

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results

Aug 2, 2023, 8:16 AM EDT - 2 years ago

Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.

CYTH

Jun 13, 2023, 4:01 PM EDT - 2 years ago

Rafael Holdings Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update

Jun 5, 2023, 8:05 AM EDT - 2 years ago

Cyclo Therapeutics Announces Execution of Definitive Agreement with Rafael Holdings, Inc. Providing for $5.0 Million of Additional Funding Via a Private Placement

CYTH

May 2, 2023, 8:12 AM EDT - 3 years ago

Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL)

CYTH

Apr 4, 2023, 8:00 AM EDT - 3 years ago

Rafael Holdings Announces up to $5 Million Share Repurchase Program

Mar 14, 2023, 4:01 PM EDT - 3 years ago

Rafael Holdings Reports Second Quarter Fiscal 2023 Financial Results

Dec 13, 2022, 7:00 AM EST - 3 years ago

Rafael Holdings Reports First Quarter Fiscal 2023 Financial Results

Nov 15, 2022, 4:01 PM EST - 3 years ago

Rafael Holdings to Focus on Strategic Business Development Initiatives and Curtail Early Stage Development Activities

Oct 31, 2022, 4:01 PM EDT - 3 years ago

Rafael Holdings Reports Fourth Quarter Fiscal 2022 Financial Results

Sep 28, 2022, 7:00 AM EDT - 3 years ago

Cornerstone Pharmaceuticals Initiates Phase 1 Trial of CPI-613® (devimistat) in Combination with Chemoradiation for the Treatment of Advanced Pancreatic Cancer

Aug 23, 2022, 7:43 AM EDT - 3 years ago

Rafael Holdings Sells its Building Located at 520 Broad Street in Newark, New Jersey and Associated 800-Car Public Garage

Jul 6, 2022, 8:00 AM EDT - 3 years ago

Cornerstone Pharmaceuticals Strengthens Scientific Advisory Board with the Appointment of Distinguished Scholar Jason Locasale, Ph.D.

Jun 16, 2022, 2:14 PM EDT - 4 years ago

Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism – UPDATE

Jun 16, 2022, 8:00 AM EDT - 4 years ago

Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism

Jun 14, 2022, 4:01 PM EDT - 4 years ago

Rafael Holdings Reports Third Quarter Fiscal 2022 Financial Results

Jun 1, 2022, 8:00 AM EDT - 4 years ago

Cornerstone Pharmaceuticals to Present Pancreatic Cancer, Clear Cell Sarcoma and Biliary Tract Cancer Research Featuring CPI-613® (Devimistat) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

May 24, 2022, 11:04 AM EDT - 4 years ago

European Medicines Agency Grants Orphan Drug Designation to Cornerstone Pharmaceuticals' CPI-613® (Devimistat) for Treatment of Patients with Advanced Unresectable Biliary Tract Cancer

Mar 17, 2022, 4:01 PM EDT - 4 years ago

Rafael Holdings Reports Second Quarter Fiscal 2022 Financial Results

Mar 11, 2022, 4:00 PM EST - 4 years ago

The Law Offices of Frank R. Cruz Continues Its Investigation of Rafael Holdings, Inc. (RFL) on Behalf of Investors

Mar 10, 2022, 2:00 PM EST - 4 years ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of Rafael Holdings, Inc. (RFL) on Behalf of Investors

Mar 7, 2022, 7:00 PM EST - 4 years ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Rafael Holdings, Inc. (RFL) on Behalf of Investors

Mar 7, 2022, 2:26 PM EST - 4 years ago

The Law Offices of Frank R. Cruz Announces Investigation of Rafael Holdings, Inc. (RFL) on Behalf of Investors

AnthonyRogers215 Feb. 21 at 8:55 AM

$RFL Rafael Holdings invests in healthcare assets. Valuation depends on subsidiary performance. Complexity adds risk.

0 · Reply

sg44 Feb. 20 at 2:54 PM

$RFL

0 · Reply

Logan_Rippenkroger Feb. 20 at 7:33 AM

$RFL https://www.linkedin.com/feed/update/ugcPost:7429547722858471426?trk=feed_main-feed-card_social-actions-comments Surprised I haven’t see this posted. Scroll through the comments….

1 · Reply

northmark1 Feb. 19 at 6:56 PM

$RFL How Many Ways Can You Spell Failure RFL!

0 · Reply

CaseOfTheYips1 Feb. 19 at 5:25 PM

$RFL 10K shares on a coma pulse…

0 · Reply

GDS_investing Feb. 19 at 3:30 PM

$RFL looking good reversal mode need more volume need to cross 1.32 for fast runup LONG

0 · Reply

sg44 Feb. 18 at 12:56 PM

0 · Reply

equtz Feb. 18 at 1:12 AM

$RFL this is probably junk but if nothing happens soon the bottom will fall out. buying with stops in place, but 50 cent downside with 3 point upside is a good spec, imo

0 · Reply

sg44 Feb. 17 at 10:56 PM

$RFL

0 · Reply

CaseOfTheYips1 Feb. 17 at 10:02 PM

$RFL presentation was a whopper… 👎🏽 Next milestone is the quarterly this week or next… not expecting much there… then Apr-Jun should have readout and our fates sealed…

0 · Reply

SentimentScribe Feb. 17 at 3:50 PM

$RFL Rafael or unknown micro-cap with minimal public information and likely speculative.

0 · Reply

snipethad Feb. 17 at 8:20 AM

$RFL Obscure micro-cap; likely illiquid

0 · Reply

sg44 Feb. 12 at 9:53 PM

$RFL article out today lists our trial alongside big pharma. Beyond amyloid: Emerging drug targets for Alzheimer’s https://share.google/ZzJrD1YWvSvbuTGeA

1 · Reply

sg44 Feb. 12 at 6:04 PM

$RFL

0 · Reply

Love_To_Learn Feb. 12 at 12:58 PM

$JZXN 1.52 SUPER FILLER ACTIVATED FOR MARKETS BELONGS TO $RFL NOW CYTH!

0 · Reply

Bjorn_Slippy Feb. 11 at 4:44 PM

$RFL no more hiding for team cyclo - only 4-5 months left of this perilous and (possibily ruinous) 6 year journey that i and others have been on - at this stage in the game dreams of a super duper slam dunk home run finish is a distant memory -— would be grateful just to get my entry fee for this rollercoaster ride refunded back to me!

0 · Reply

sg44 Feb. 11 at 2:42 PM

$RFL added

0 · Reply

DriftObserver Feb. 10 at 2:51 PM

$RFL is a Rafael or defense company; reliant on government contracts.

1 · Reply

CaseOfTheYips1 Feb. 6 at 6:46 PM

$RFL $1.40+ by close

0 · Reply

CaseOfTheYips1 Feb. 6 at 6:32 PM

$RFL run you beautiful little cripple, you can do it!!!

0 · Reply

Fashtrades Feb. 6 at 6:13 PM

$RFL Let’s goooo

0 · Reply

Sashko2018 Feb. 6 at 5:54 PM

$RFL news coming soon

0 · Reply

Market Cap	63.68M
Revenue (ttm)	920,000.00
Net Income (ttm)	-30.52M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-3,317.39%
Debt to Equity Ratio	0.01

Volume	34,300
Avg Vol	117,486
Day's Range	N/A - N/A
Shares Out	51.77M
Stochastic %K	58%
Beta	0.68
Analysts	Strong Buy
Price Target	N/A